Pila Pharma AB is developing XEN-D0501, a TRPV1 antagonist designed for oral treatment of Type 2 diabetes and obesity. The company is preparing a Phase 2a clinical trial to evaluate the safety, tolerability, and effects on blood glucose and body weight in overweight or obese individuals with diabetes.
Funding
$944.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for Type 2 diabetes and obesity often have limited efficacy or significant side effects. There remains a need for novel therapeutics that can effectively manage blood glucose levels and body weight with improved safety and tolerability profiles.
Solution
Pila Pharma is developing XEN-D0501, an orally administered TRPV1 antagonist, as a potential treatment for Type 2 diabetes and obesity. XEN-D0501 targets the capsaicin receptor, offering a unique mechanism of action for managing metabolic diseases. The drug is currently undergoing Phase 2a clinical trials to assess its safety, tolerability, and effects on blood glucose and body weight in overweight or obese individuals with diabetes. Early studies have also suggested a strong cardiovascular profile, indicating potential benefits beyond glucose regulation and weight reduction.
Target Audience
The primary target audience includes individuals with Type 2 diabetes and obesity, as well as healthcare providers seeking new therapeutic options for these conditions.
Features
- Orally administered TRPV1 antagonist
- Targets the capsaicin receptor
- Designed for the treatment of Type 2 diabetes and obesity
- Aims to regulate blood glucose levels
- Aims to reduce body weight
- May offer a beneficial cardiovascular profile
- Currently in Phase 2a clinical development